DENTSPLY SIRONA Inc. (XRAY) Position Held by South State Corp

South State Corp continued to hold its stake in DENTSPLY SIRONA Inc. (NASDAQ:XRAY) during the first quarter, according to its most recent filing with the SEC. The fund owned 6,900 shares of the medical instruments supplier’s stock at the end of the first quarter. South State Corp’s holdings in DENTSPLY SIRONA were worth $431,000 as of its most recent SEC filing.

Other institutional investors also recently bought and sold shares of the company. JNBA Financial Advisors raised its position in DENTSPLY SIRONA by 803.0% in the fourth quarter. JNBA Financial Advisors now owns 2,420 shares of the medical instruments supplier’s stock valued at $140,000 after buying an additional 2,152 shares during the last quarter. Howard Hughes Medical Institute raised its position in DENTSPLY SIRONA by 134.9% in the first quarter. Howard Hughes Medical Institute now owns 2,751 shares of the medical instruments supplier’s stock valued at $172,000 after buying an additional 1,580 shares during the last quarter. Perennial Advisors LLC acquired a new position in shares of DENTSPLY SIRONA during the fourth quarter worth $185,000. Howland Capital Management LLC acquired a new position in shares of DENTSPLY SIRONA during the first quarter worth $203,000. Finally, Focused Wealth Management Inc raised its position in shares of DENTSPLY SIRONA by 179.2% in the fourth quarter. Focused Wealth Management Inc now owns 4,051 shares of the medical instruments supplier’s stock worth $234,000 after buying an additional 2,600 shares in the last quarter. Institutional investors own 95.29% of the company’s stock.

Institutional Ownership by Quarter for DENTSPLY SIRONA (NASDAQ:XRAY)

Shares of DENTSPLY SIRONA Inc. (NASDAQ:XRAY) traded up 0.62% on Friday, hitting $63.70. 1,700,481 shares of the stock traded hands. DENTSPLY SIRONA Inc. has a 52-week low of $55.00 and a 52-week high of $65.83. The firm has a market cap of $14.60 billion, a PE ratio of 40.99 and a beta of 1.25. The firm has a 50 day moving average price of $63.20 and a 200 day moving average price of $61.05.

DENTSPLY SIRONA (NASDAQ:XRAY) last announced its quarterly earnings data on Tuesday, May 9th. The medical instruments supplier reported $0.49 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $0.50 by $0.01. The business had revenue of $900.50 million during the quarter, compared to the consensus estimate of $916.55 million. DENTSPLY SIRONA had a net margin of 9.42% and a return on equity of 7.37%. The business’s revenue was up 16.6% compared to the same quarter last year. During the same period last year, the company earned $0.69 EPS. On average, equities analysts forecast that DENTSPLY SIRONA Inc. will post $2.84 EPS for the current year.

TRADEMARK VIOLATION WARNING: This news story was first published by Markets Daily and is the sole property of of Markets Daily. If you are reading this news story on another site, it was copied illegally and reposted in violation of U.S. & international copyright and trademark laws. The correct version of this news story can be read at https://www.themarketsdaily.com/2017/06/16/south-state-corp-has-431000-position-in-dentsply-sirona-inc-xray-updated-updated.html.

A number of brokerages have weighed in on XRAY. BidaskClub lowered shares of DENTSPLY SIRONA from a “buy” rating to a “hold” rating in a research report on Saturday, June 10th. Cleveland Research upgraded shares of DENTSPLY SIRONA from a “neutral” rating to a “buy” rating in a research report on Tuesday, May 23rd. Goldman Sachs Group, Inc. (The) lowered shares of DENTSPLY SIRONA from a “neutral” rating to a “sell” rating and cut their target price for the stock from $60.00 to $55.00 in a research report on Tuesday, May 23rd. Zacks Investment Research raised shares of DENTSPLY SIRONA from a “sell” rating to a “hold” rating and set a $71.00 price target on the stock in a report on Tuesday, May 2nd. Finally, Barrington Research downgraded shares of DENTSPLY SIRONA from an “outperform” rating to a “market perform” rating in a report on Tuesday, February 21st. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and eight have given a buy rating to the company. The company has a consensus rating of “Buy” and a consensus price target of $66.44.

In related news, CEO Christopher T. Clark sold 89,700 shares of the firm’s stock in a transaction dated Friday, April 7th. The stock was sold at an average price of $62.67, for a total transaction of $5,621,499.00. Following the sale, the chief executive officer now owns 112,067 shares of the company’s stock, valued at $7,023,238.89. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO James G. Mosch sold 50,600 shares of the firm’s stock in a transaction dated Monday, April 24th. The shares were sold at an average price of $63.49, for a total value of $3,212,594.00. Following the sale, the chief executive officer now directly owns 105,083 shares in the company, valued at approximately $6,671,719.67. The disclosure for this sale can be found here. 1.99% of the stock is currently owned by corporate insiders.

DENTSPLY SIRONA Company Profile

DENTSPLY SIRONA Inc is a manufacturer of professional dental products and technologies. The Company develops, manufactures, and markets solutions offering, including dental and oral health products, as well as other consumable medical devices. It operates through two segments: Dental and Healthcare Consumables, and Technologies.

Receive News & Ratings for DENTSPLY SIRONA Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DENTSPLY SIRONA Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply